Bicara Therapeutics (BCAX) vs Immunome (IMNM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunome (IMNM) has outperformed Bicara Therapeutics (BCAX) over the past year, gaining 37.8% versus a loss of 4.1%. Immunome is the larger company by market cap ($2.32 billion vs $1.18 billion), about 2.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | IMNM |
|---|---|---|
| Share price | $17.76 | $19.66 |
| Market cap | $1.18B | $2.32B |
| 1-day change | +2.90% | +1.81% |
| YTD return | +2.55% | -10.10% |
| 1-year return | -4.11% | +37.83% |
| 5-year return | — | +9.65% |
| EPS (TTM) | $-3.08 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $6.94M |
| Revenue growth (YoY) | — | -23.23% |
| Net income (latest FY) | — | $-212.39M |
| Operating margin | — | -3228.83% |
| Net margin | — | -3059.99% |
| 52-week high | $30.99 | $30.06 |
| 52-week low | $13.70 | $13.49 |
| Distance from 52-week high | -42.69% | -34.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +99.89% | +79.04% |
| Average volume | 623.17K | 1.20M |
| Shares outstanding | 66.17M | 118.00M |
| Employees | 103 | 247 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMNM has outperformed BCAX by 41.9 percentage points over the past year.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
BCAX vs IMNM FAQ
Which is bigger, Bicara Therapeutics or Immunome?
Immunome (IMNM) is larger, with a market capitalization of $2.32B compared with $1.18B for Bicara Therapeutics (BCAX).
Which stock has performed better over the past year, BCAX or IMNM?
IMNM returned +37.83% over the past 12 months, compared with -4.11% for BCAX (price return, excluding dividends). Past performance does not predict future results.
Are Bicara Therapeutics and Immunome in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.